Mulla N F, Johnston J K, Vander Dussen L, Beeson W L, Chinnock R E, Bailey L L, Larsen R L
Department of Pediatrics, Loma Linda University Children's Hospital, California, USA.
J Am Coll Cardiol. 2001 Jan;37(1):243-50. doi: 10.1016/s0735-1097(00)01037-8.
The study objectives were to determine posttransplant coronary artery disease (TxCAD) incidence, predisposing factors and optimal timing for retransplantation (re-Tx) in pediatric heart transplantation (Tx) recipients.
The TxCAD limits long-term survival following heart Tx, with re-Tx being the primary therapy. Information on risk factors and timing of listing for re-Tx is limited in children.
The records of children who survived >1 year post-Tx at Loma Linda University were reviewed. Nonimmune and immune risk factors were analyzed.
TxCAD was documented in 24 of 210 children. Freedom from TxCAD was 92 +/- 2% and 75 +/- 5% at 5 and 10 years' post-Tx, respectively. The TxCAD diagnosis was established at autopsy in 10 asymptomatic patients who died suddenly within nine months following the most recent negative angiograms. The remaining 14 children had angiographic diagnoses of TxCAD and had symptoms and/or graft dysfunction (n = 10) or positive stress studies (n = 4). Three of 14 died within three months after the diagnosis was made. Eleven patients underwent re-Tx within seven months of diagnosis; nine survived. Univariate and multivariate analyses showed that only late rejection (>1 year posttransplant) frequency (p = 0.025) and severity (hemodynamically compromising) (p < 0.01) were independent predictors of TxCAD development. Freedom from TxCAD after severe late rejection was 78 +/- 8% one year postevent and 55 +/- 10% by two years.
Late rejection is an independent predictor of TxCAD. Patients suffering severe late rejection develop angiographically apparent TxCAD rapidly and must be monitored aggressively. Both TxCAD mortality and morbidity occur early; therefore, we recommend immediate listing for re-Tx upon diagnosis.
本研究的目的是确定小儿心脏移植受者移植后冠心病(TxCAD)的发病率、诱发因素以及再次移植(re-Tx)的最佳时机。
TxCAD限制了心脏移植后的长期生存,再次移植是主要治疗方法。关于儿童再次移植的危险因素和列入名单的时机的信息有限。
回顾了洛马林达大学移植后存活超过1年的儿童的记录。分析了非免疫和免疫危险因素。
210名儿童中有24名被记录患有TxCAD。移植后5年和10年时无TxCAD的概率分别为92±2%和75±5%。10例无症状患者在最近一次血管造影阴性后9个月内突然死亡,尸检确诊为TxCAD。其余14名儿童经血管造影诊断为TxCAD,有症状和/或移植物功能障碍(n = 10)或负荷试验阳性(n = 4)。14名患者中有3名在诊断后3个月内死亡。11名患者在诊断后7个月内接受了再次移植;9名存活。单因素和多因素分析显示,只有晚期排斥反应(移植后>1年)的频率(p = 0.025)和严重程度(血流动力学受损)(p < 0.01)是TxCAD发生的独立预测因素。严重晚期排斥反应后1年无TxCAD的概率为78±8%,2年时为55±10%。
晚期排斥反应是TxCAD的独立预测因素。发生严重晚期排斥反应的患者会迅速出现血管造影可见的TxCAD,必须积极监测。TxCAD的死亡率和发病率均出现较早;因此,我们建议一旦确诊应立即列入再次移植名单。